BioSpace News Archive

Boundless Bio today will present preclinical data on its second ecDNA-directed therapy (ecDTx), BBI-825, as well as present additional research on the intrinsic genomic plasticity of cancer cells enabled by ecDNA at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will discontinue the currently ongoing clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab.

Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg product candidate for the treatment of hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA).

Faeth Therapeutics proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100’s Most Influential People, into the esteemed National Academy of Medicine.

Foresee Pharmaceuticals, announces that the first patient has been dosed in the Casppian Phase 3 registration study.

Hyundai Bioscience announced that Xafty™, a broad-spectrum antiviral drug, can solve RNA virus infections, capable of treating both COVID-19 and Dengue fever or Dengue virus infection”.

Galderma, the emerging pure-play dermatology category leader, hosts the first edition of its Liquid Live event in Dubai as a chance to discuss with clinicians the future of innovation in the field of neuromodulation as well as showcasing the latest neuromodulators from its aesthetics portfolio.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP).

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.